BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen® Product Development

BioTime, Inc. BTX announced today that Charles S. Irving, Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd. will provide an update on the development of OpRegen® at an investor meeting in New York City. In his presentation, Dr. Irving will describe the unmet medical needs and markets for the treatment of the dry form of age-related macular degeneration (AMD), and the advantages of Cell Cure's OpRegen which has been produced from human embryonic stem cells in culture conditions free of animal products, eliminating the need for designating the product as a xenotransplantation therapeutic. Dr. Irving will also discuss Cell Cure's collaboration with Teva Pharmaceutical Industries Ltd., under which Teva has the option to develop and commercialize both OpRegen® and OpRegen-Plus®. Dr. Irving will describe the nature of the ongoing preclinical studies which are expected to lead to regulatory filings for the initiation of human clinical trials in 2013. Dr. Irving's presentation will be available on BioTime's web site www.biotimeinc.com as well as Cell Cure Neuroscience's web site at www.cellcureneurosciences.com.